Tvardi Therapeutics announced the development of its oral STAT3 inhibitor, TTI-109, to treat patients with ulcerative colitis [1].
The move targets a significant gap in current medical care. More than 70% of ulcerative colitis patients do not achieve clinical remission using existing therapies [2].
Based in Houston, Texas, the company first identified ulcerative colitis as the initial indication for TTI-109 in a press release on July 30, 2026 [3]. The drug is designed as a STAT3 inhibitor, a mechanism intended to address the inflammatory processes associated with the disease.
On August 19, 2026, Tvardi hosted a virtual webinar featuring key opinion leaders to discuss the development program and present clinical data [1]. The session provided a detailed look at the TTI-109 program and the evidence supporting its use in patients who have failed other treatments.
Ulcerative colitis is a chronic inflammatory bowel disease that causes inflammation and ulcers in the digestive tract. Because a majority of patients remain symptomatic despite current drug options [2], Tvardi is positioning TTI-109 as a potential alternative for those who do not respond to standard care.
The company, traded on the NASDAQ under the symbol TVRD, continues to advance the TTI-109 program through its clinical pipeline [1]. The virtual presentation served as a primary vehicle for sharing the company's current data with the medical community and investors.
“More than 70% of ulcerative colitis patients do not achieve clinical remission with current therapies”
The focus on a STAT3 inhibitor represents an attempt to provide a new pharmacological pathway for patients who are refractory to existing biologics or corticosteroids. If TTI-109 proves effective, it could shift the treatment paradigm for the significant percentage of the ulcerative colitis population that currently lacks a viable path to clinical remission.
